Skip to Content

Ceo-Two (potassium bitartrate / sodium bicarbonate) Disease Interactions

There are 3 disease interactions with Ceo-Two (potassium bitartrate / sodium bicarbonate):

Major

Alkalinizing agents (Includes Ceo-Two) ↔ sodium/water balance

Severe Potential Hazard, High plausibility. Applies to: Congestive Heart Failure, Fluid Retention, Hypernatremia

Alkalinizing agents containing sodium can induce sodium and water retention and result in hypernatremia, hypokalemia, hyperosmolality, edema and aggravation of congestive heart failure. Therapy with sodium- containing alkalinizing agents should not be used in patients with hypernatremia or fluid retention. Clinical monitoring of acid/base balance and electrolytes prior to, during, a following completion of therapy with alkalinizing agents is recommended.

References

  1. "Product Information. Sodium Bicarbonate (sodium bicarbonate)." Astra USA, Westborough, MA.
  2. "Product Information. Sodium Lactate (sodium lactate)." Abbott Pharmaceutical, Abbott Park, IL.
Major

Laxatives (Includes Ceo-Two) ↔ inflammatory bowel disease

Severe Potential Hazard, Moderate plausibility. Applies to: Inflammatory Bowel Disease

The use of laxatives is contraindicated in patients with inflammatory bowel disease. Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.

References

  1. "Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc, Woodbridge, NJ.
  2. "Product Information. Fleet Bisacodyl Enema (bisacodyl)." Fleet, Lynchburg, VA.
Major

Laxatives (Includes Ceo-Two) ↔ intestinal obstruction disorders

Severe Potential Hazard, Moderate plausibility. Applies to: Gastrointestinal Obstruction

The use of laxatives is contraindicated in patients with intestinal obstruction disorders. Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation. Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.

References

  1. "Product Information. Kondremul (mineral oil)." Bristol-Myers Squibb, Princeton, NJ.
  2. "Product Information. Fleet Bisacodyl Enema (bisacodyl)." Fleet, Lynchburg, VA.
  3. "Product Information. Fleet Babylax (glycerin)." Alcon Laboratorries Inc, Fort Worth, TX.
  4. "Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc, Woodbridge, NJ.
  5. "Product Information. Fleet Mineral Oil Enema (mineral oil)." Fleet, Lynchburg, VA.
View all 5 references

Ceo-Two (potassium bitartrate / sodium bicarbonate) drug interactions

There are 586 drug interactions with Ceo-Two (potassium bitartrate / sodium bicarbonate)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide